358 related articles for article (PubMed ID: 18184225)
21. Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy.
Sergott RC; Bittman RM; Christen EM; Sagar SM
Epilepsy Res; 2010 Dec; 92(2-3):170-6. PubMed ID: 20951555
[TBL] [Abstract][Full Text] [Related]
22. [Epilepsy and Sabril].
Depasse F
Bull Soc Belge Ophtalmol; 2007; (304):33-40. PubMed ID: 17718226
[TBL] [Abstract][Full Text] [Related]
23. Vigabatrin: an effective antiepilepsy drug--balancing the risk of visual dysfunction.
Krauss GL; Miller NR
Ann Pharmacother; 1999 Dec; 33(12):1367-8. PubMed ID: 10630838
[No Abstract] [Full Text] [Related]
24. Are vigabatrin-associated visual field constrictions asymptomatic?
Schmidt T; Rüther K; Schmitz B
J Neurol; 2004 Jul; 251(7):887-8. PubMed ID: 15258797
[No Abstract] [Full Text] [Related]
25. Epilepsy: Vigabatrin treatment and visual field loss.
Chiron C; Dulac O
Nat Rev Neurol; 2011 Apr; 7(4):189-90. PubMed ID: 21364521
[No Abstract] [Full Text] [Related]
26. Is the risk of vigabatrin-attributed visual field loss lower in infancy than in later life?
Riikonen R
Epilepsia; 2009 Aug; 50(8):2005-6. PubMed ID: 19682035
[No Abstract] [Full Text] [Related]
27. Visual fields in young children treated with vigabatrin.
Agrawal S; Mayer DL; Hansen RM; Fulton AB
Optom Vis Sci; 2009 Jun; 86(6):767-73. PubMed ID: 19417698
[TBL] [Abstract][Full Text] [Related]
28. Visual field defect associated with vigabatrin. Method of estimating prevalence was inappropriate.
Manuchehri K
BMJ; 2000 May; 320(7246):1403-4; author reply 1404. PubMed ID: 10858055
[No Abstract] [Full Text] [Related]
29. [Visual field changes secondary to vigabatrin treatment].
Mauri-Llerda JA; Iñiguez C; Tejero-Juste C; Santos-Lasaosa S; Escalza-Cortina I; Ascaso-Puyuelo J; Abad-Alegría F; Morales-Asín F
Rev Neurol; 2000 Dec 16-31; 31(12):1104-8. PubMed ID: 11205539
[TBL] [Abstract][Full Text] [Related]
30. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity.
Lawthom C; Smith PE; Wild JM
Ophthalmology; 2009 Mar; 116(3):565-71. PubMed ID: 19168223
[TBL] [Abstract][Full Text] [Related]
31. [The function of eye and vision system in children and youth treated with vigabatrin--our own experiences].
Pojda-Wilczek D; Emich-Widera E; Herba E; Pojda SM; Marszał E
Klin Oczna; 2005; 107(10-12):654-7. PubMed ID: 16619812
[TBL] [Abstract][Full Text] [Related]
32. Visual field constriction in 91 Finnish children treated with vigabatrin.
Vanhatalo S; Nousiainen I; Eriksson K; Rantala H; Vainionpää L; Mustonen K; Aärimaa T; Alen R; Aine MR; Byring R; Hirvasniemi A; Nuutila A; Walden T; Ritanen-Mohammed UM; Karttunen-Lewandowski P; Pohjola LM; Kaksonen S; Jurvelin P; Granström ML
Epilepsia; 2002 Jul; 43(7):748-56. PubMed ID: 12102679
[TBL] [Abstract][Full Text] [Related]
33. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose.
Kinirons P; Cavalleri GL; O'Rourke D; Doherty CP; Reid I; Logan P; Liggan B; Delanty N
Epilepsia; 2006 Feb; 47(2):311-7. PubMed ID: 16499754
[TBL] [Abstract][Full Text] [Related]
34. Visual fields in children exposed to vigabatrin in infancy.
Gaily E; Jonsson H; Lappi M
Epilepsia; 2010 Jul; 51(7):1329-30. PubMed ID: 20636970
[No Abstract] [Full Text] [Related]
35. Visual field defect associated with vigabatrin. Means of selecting patients was misleading.
Midelfart A
BMJ; 2000 May; 320(7246):1404. PubMed ID: 10858056
[No Abstract] [Full Text] [Related]
36. [Visual field changes as a side effect of treatment with vigabatrin therapy].
Kobylański P
Neurol Neurochir Pol; 2000; 34(3):597-9. PubMed ID: 10979552
[No Abstract] [Full Text] [Related]
37. Ophthalmologic and neurologic findings in two children exposed to vigabatrin in utero.
Sorri I; Herrgård E; Viinikainen K; Pääkkönen A; Heinonen S; Kälviäinen R
Epilepsy Res; 2005 Jun; 65(1-2):117-20. PubMed ID: 15941649
[TBL] [Abstract][Full Text] [Related]
38. The natural history of Vigabatrin-associated visual field defects in patients electing to continue their medication.
Kumar N; Jivan S
Eye (Lond); 2006 Sep; 20(9):1082-3; author reply 1083-4. PubMed ID: 16244645
[No Abstract] [Full Text] [Related]
39. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile.
Camposano SE; Major P; Halpern E; Thiele EA
Epilepsia; 2008 Jul; 49(7):1186-91. PubMed ID: 18479386
[TBL] [Abstract][Full Text] [Related]
40. GABA and the ornithine delta-aminotransferase gene in vigabatrin-associated visual field defects.
Hisama FM; Mattson RH; Lee HH; Felice K; Petroff OA
Seizure; 2001 Oct; 10(7):505-7. PubMed ID: 11749107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
